Bioventus Inc. - Class A Common Stock (BVS)

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81.

BVS stock results show that Bioventus beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Learn more about the growth stocks under $10 with progressive fundamentals in the healthcare and technology sectors.

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

BVS stock results show that Bioventus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results.

U.S. stocks were higher, with the Dow Jones index surging more than 200 points on Tuesday.

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.